Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

(2012) Eamonn S. Molloy et al.   ARTHRITIS AND RHEUMATISM

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

(2012) Fabiola Atzeni et al.   AUTOIMMUNITY REVIEWS

Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)

(2012) Niklas Schmedt et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

(2011) J. R. Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

(2011) D. E. Furst et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis

(2011) F. Conti et al.   RHEUMATOLOGY

Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

(2011) Cándido Díaz-Lagares et al.   ARTHRITIS RESEARCH & THERAPY

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

(2011) Hans-Peter Tony et al.   ARTHRITIS RESEARCH & THERAPY

EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology

(2010) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

(2010) Benjamin Terrier et al.   ARTHRITIS AND RHEUMATISM

Infections in polymyositis and dermatomyositis: analysis of 192 cases

(2010) I.-J. Chen et al.   RHEUMATOLOGY

Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0

(2010) L. Carmona et al.   RHEUMATOLOGY

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Predictors of major infections in systemic lupus erythematosus

(2009) Guillermo Ruiz-Irastorza et al.   ARTHRITIS RESEARCH & THERAPY

A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases

(2008) Manuel Ramos-Casals et al.   MEDICINE